Paclitaxel / MMP11 Cancer Research Results

PacT, Paclitaxel: Click to Expand ⟱

Features:

Paclitaxel (brand name Taxol) is a chemotherapy medication used to treat ovarian cancer, esophageal cancer, breast cancer, lung cancer, Kaposi's sarcoma, cervical cancer, and pancreatic cancer. Administered by intravenous injection.
Derived from a natural product, Taxol (from Pacific Yew Tree).
Paclitaxel is a drug (chemotherapy; a taxane). Its dominant anticancer mechanism is microtubule stabilization, which disrupts normal mitosis and drives mitotic arrest/stress signaling that can culminate in apoptosis.

Paclitaxel – Cancer Pathway Matrix

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	Microtubule stabilization → Mitotic arrest	Mitotic progression ↓; spindle dynamics impaired; cell division blocked	Proliferating normal cells affected	R, G	Core cytotoxic mechanism	Binds β-tubulin and stabilizes microtubules, preventing normal depolymerization required for mitosis.
2	Spindle assembly checkpoint activation	Prolonged mitotic arrest → mitotic catastrophe or apoptosis	Checkpoint stress in dividing tissues	R, G	Mitotic stress execution	Cell fate depends on whether arrest resolves via apoptosis or mitotic slippage.
3	Intrinsic apoptosis (mitochondrial pathway)	Caspase activation ↑; BAX/mitochondrial signaling engaged (context)	Limited unless stressed	G	Cell death execution	Often downstream of prolonged mitotic stress and mitochondrial perturbation.
4	ROS generation (secondary)	ROS ↑ (context-dependent); oxidative stress amplification	Oxidative stress possible in sensitive tissues	R, G	Stress amplifier	ROS rise appears secondary to mitotic and mitochondrial dysfunction; may enhance apoptosis.
5	Nrf2 antioxidant response (adaptive)	Nrf2 ↑ in some tumors; antioxidant buffering ↑; resistance potential	Protective antioxidant signaling	G	Adaptive resistance axis	Not a direct paclitaxel target; elevated Nrf2 may reduce drug sensitivity.
6	Drug resistance mechanisms	P-glycoprotein (MDR1) ↑; β-tubulin alterations; survival rewiring	—	G	Treatment failure driver	Efflux pumps and tubulin adaptations are major clinical resistance mechanisms.
7	Myelosuppression	—	Neutropenia risk ↑	G	Dose-limiting toxicity	Bone marrow suppression is a primary clinical constraint.
8	Peripheral neuropathy	—	Sensory neuropathy risk ↑	G	Dose-limiting toxicity	Likely related to microtubule disruption in axonal transport.

Time-Scale Flag (TSF):
P = 0–30 min (drug binding begins)
R = 30 min–3 hr (mitotic stress signaling, ROS changes)
G = >3 hr (apoptosis, resistance adaptation, tissue toxicities)

MMP11, matrix metalloproteinase 11: Click to Expand ⟱

Source:

Type:

A type of enzyme that plays a role in the breakdown of the extracellular matrix, a network of proteins and other molecules that provide structural support to cells and tissues.
MMP11 is overexpressed in various types of cancer, including breast, lung, colon, and prostate cancer. High levels of MMP11 have been associated with poor prognosis and reduced survival in cancer patients.

Scientific Papers found: Click to Expand⟱

299-

ALA,

Cisplatin,

PacT,

Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line

in-vitro,

Ovarian,

OVCAR-3

MMP9↓, MMP11↓, MAPK↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Cell Death ⓘ

MAPK↓, 1,

Migration ⓘ

MMP11↓, 1, MMP9↓, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: MMP11, matrix metalloproteinase 11

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells